Full TitleA Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Involved-Site Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
The standard therapy for early-stage Hodgkin lymphoma that has a high risk of returning after treatment is chemotherapy with four drugs (doxorubicin, bleomycin, vinblastine, and dacarbazine) followed by radiation therapy. However, despite this approach, the cancer still returns in about 20 percent of patients.
In this study, researchers are assessing a different approach: the drugs doxorubicin, vinblastine, and dacarbazine plus another drug called brentuximab vedotin (which is already approved by the U.S. Food and Drug Administration for treating Hodgkin lymphoma which persists despite other treatments), followed by radiation therapy. It is hoped that this regimen will be more effective than the standard treatment for reducing the risk of cancer recurrence in patients with early-stage poor-risk Hodgkin lymphoma that has not yet been treated.
Brentuximab has two parts: one (an antibody) that attaches to a protein on the surface of cancer cells called CD30, and another (an anticancer drug called monomethyl auristatin E) that kills the cancer.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have stage I or II poor-risk Hodgkin lymphoma that has not yet been treated.
- Patients’ cancers must be positive for the CD30 protein (the target of brentuximab).
- This study is open to patients age 18 to 60.
For more information about this study and to inquire about eligibility, please contact Dr. Craig Moskowitz at 212-639-2696.